BR0308401A - Anticorpo humano anti-hfasl isolado, ou porção de ligação de antìgeno do mesmo, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para inibir as atividades de hfasl, e de fasl, e para tratar ou prevenir um distúrbio no qual a atividade de fasl é prejudicial, composição farmacêutica, e, uso de anticorpo ou de fragmento. - Google Patents

Anticorpo humano anti-hfasl isolado, ou porção de ligação de antìgeno do mesmo, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para inibir as atividades de hfasl, e de fasl, e para tratar ou prevenir um distúrbio no qual a atividade de fasl é prejudicial, composição farmacêutica, e, uso de anticorpo ou de fragmento.

Info

Publication number
BR0308401A
BR0308401A BR0308401-9A BR0308401A BR0308401A BR 0308401 A BR0308401 A BR 0308401A BR 0308401 A BR0308401 A BR 0308401A BR 0308401 A BR0308401 A BR 0308401A
Authority
BR
Brazil
Prior art keywords
hfasl
antibody
fasl
disorder
activity
Prior art date
Application number
BR0308401-9A
Other languages
English (en)
Inventor
Joanne Sloan Lancaster
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0308401A publication Critical patent/BR0308401A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)

Abstract

"ANTICORPO HUMANO ANTI-HFASL ISOLADO, OU PORçãO DE LIGAçãO DE ANTìGENO DO MESMO, MOLéCULA DE áCIDO NUCLEICO ISOLADA, VETOR, CéLULA HOSPEDEIRA, MéTODOS PARA INIBIR AS ATIVIDADES DE hFasL, E DE FasL, E PARA TRATAR OU PREVENIR UM DISTúRBIO NO QUAL A ATIVIDADE DE FasL é PREJUDICIAL, COMPOSIçãO FARMACêUTICA, E, USO DE ANTICORPO OU DE FRAGMENTO". Anticorpos humanos, preferivelmente anticorpos humanos recombinantes que especificamente se ligam em Ligando Fas humano (hFaL) são descritos. Estes anticorpos possuem alta afinidade por hFasL, uma velocidade lenta para dissociação de hFasL e neutralizam uma atividade de Ligando Fas in vitro e in vivo. Um anticorpo da invenção pode ser um anticorpo de comprimento total ou uma sua porção de ligação de antígeno. Os anticorpos, ou porções de ligação de antígeno, da invenção são úteis para neutralizar a atividade de Ligando Fas, por exemplo, em um individuo humano sofrendo de um distúrbio no qual a atividade de Ligando Fas é prejudicial. ácidos nucleicos, vetores e células hospedeiras para a expressão de anticorpos humanos anti-hFasL, e métodos para a síntese de anticorpos humanos recombinantes também estão incluídos na presente invenção.
BR0308401-9A 2002-03-21 2003-03-12 Anticorpo humano anti-hfasl isolado, ou porção de ligação de antìgeno do mesmo, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para inibir as atividades de hfasl, e de fasl, e para tratar ou prevenir um distúrbio no qual a atividade de fasl é prejudicial, composição farmacêutica, e, uso de anticorpo ou de fragmento. BR0308401A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36705402P 2002-03-21 2002-03-21
US40976802P 2002-09-10 2002-09-10
PCT/US2003/006155 WO2003079750A2 (en) 2002-03-21 2003-03-12 ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF

Publications (1)

Publication Number Publication Date
BR0308401A true BR0308401A (pt) 2005-03-29

Family

ID=28457146

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308401-9A BR0308401A (pt) 2002-03-21 2003-03-12 Anticorpo humano anti-hfasl isolado, ou porção de ligação de antìgeno do mesmo, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para inibir as atividades de hfasl, e de fasl, e para tratar ou prevenir um distúrbio no qual a atividade de fasl é prejudicial, composição farmacêutica, e, uso de anticorpo ou de fragmento.

Country Status (15)

Country Link
US (1) US7262277B2 (pt)
EP (1) EP1490405B1 (pt)
JP (1) JP2005520523A (pt)
CN (1) CN1283662C (pt)
AT (1) ATE370970T1 (pt)
AU (1) AU2003219954B2 (pt)
BR (1) BR0308401A (pt)
CA (1) CA2478386A1 (pt)
DE (1) DE60315815T2 (pt)
DK (1) DK1490405T3 (pt)
ES (1) ES2291626T3 (pt)
IL (1) IL164011A0 (pt)
MX (1) MXPA04009148A (pt)
PT (1) PT1490405E (pt)
WO (1) WO2003079750A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
ES2366626T3 (es) 2004-02-06 2011-10-24 University Of Massachusetts Anticuerpos contra toxinas de clostridium difficile y usos de los mismos.
AU2006290433B2 (en) * 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
KR20100130584A (ko) * 2007-12-12 2010-12-13 핀셀 에스알엘 항 Ｆａｓ 리간드 항체를 함유한 천포창 치료제
US20110189194A1 (en) * 2008-07-14 2011-08-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
AU2009326978B2 (en) 2008-12-12 2013-09-12 Pincell Srl Remedies for pemphigus containing anti Fas ligand antibodies
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
US20150377888A1 (en) * 2013-02-01 2015-12-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for Predicting and Preventing Metastasis in Triple Negative Breast Cancers
EP2992330B1 (en) * 2013-04-29 2018-04-18 Apogenix AG Method of diagnosing cancer
EP3137909B1 (en) 2014-04-29 2018-06-06 Apogenix AG Diagnostic anti-cd95l antibody
US20220289827A1 (en) * 2021-03-11 2022-09-15 Washington University Neutralizing antibodies to sars-cov-2 and its variants
CN116888257A (zh) * 2022-01-21 2023-10-13 北京三诺佳邑生物技术有限责任公司 特异性识别FasL的抗体及其应用
CN116829594A (zh) * 2022-01-21 2023-09-29 北京三诺佳邑生物技术有限责任公司 特异性识别FasL的抗体及其应用
JP2025514847A (ja) 2022-04-26 2025-05-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｆａｓ軸拮抗薬及びＴｒｅｇ細胞枯渇剤拮抗薬を含む癌の治療のための併用療法
WO2024114767A1 (zh) * 2022-12-01 2024-06-06 南京北恒生物科技有限公司 耐免疫排斥的工程化细胞
WO2024193714A1 (zh) * 2023-03-23 2024-09-26 科济生物医药（上海）有限公司 细胞免疫疗法的组合物和方法
EP4474395A1 (en) * 2023-06-06 2024-12-11 PinCell S.r.l. Anti-fas ligand (fasl) antibodies in the treatment of sjs/ten diseases
CN120981482A (zh) * 2023-03-24 2025-11-18 平切尔有限责任公司 抗FAS配体（FasL）抗体治疗SJS/TEN疾病
WO2025196289A1 (en) 2024-03-22 2025-09-25 Pincell S.R.L. New target affinity and specificity of anti sfas-l antibody, pc111

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
ATE387458T1 (de) 1994-01-07 2008-03-15 Mochida Pharm Co Ltd Fas-antigenbindender ligand
NZ311174A (en) * 1995-06-30 1999-04-29 Mochida Pharm Co Ltd Anti-fas ligand antibody which suppresses fas ligand-induced apoptosis in cells and method of assaying a fas ligand using the anti-fas ligand antibody
US6096312A (en) * 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
US6114507A (en) 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody

Also Published As

Publication number Publication date
CA2478386A1 (en) 2003-10-02
ATE370970T1 (de) 2007-09-15
EP1490405B1 (en) 2007-08-22
DK1490405T3 (da) 2007-12-27
AU2003219954B2 (en) 2006-11-09
EP1490405A4 (en) 2005-09-14
US20050106140A1 (en) 2005-05-19
US7262277B2 (en) 2007-08-28
CN1283662C (zh) 2006-11-08
DE60315815T2 (de) 2008-05-21
ES2291626T3 (es) 2008-03-01
WO2003079750A3 (en) 2004-05-13
WO2003079750A2 (en) 2003-10-02
DE60315815D1 (de) 2007-10-04
CN1642980A (zh) 2005-07-20
PT1490405E (pt) 2007-11-07
AU2003219954A1 (en) 2003-10-08
IL164011A0 (en) 2005-12-18
EP1490405A2 (en) 2004-12-29
JP2005520523A (ja) 2005-07-14
MXPA04009148A (es) 2005-02-28

Similar Documents

Publication Publication Date Title
BRPI0716438A8 (pt) Proteínas ligantes interleucina-1,3
BRPI9715219B8 (pt) Vetor recombinante de expressão, e célula hospedeira procariótica.
DE60315815D1 (de) ANTAGONISTISCHE HUMANE ANTI-hFAS-LIGAND-ANTIKÖRPER UND FRAGMENTE DAVON
WO2005058815A3 (en) Ip-10 antibodies and their uses
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
SG170080A1 (en) Human monoclonal antibodies to o8e
TW200738749A (en) Human antibodies that bind human IL-12 and methods for producing
MXPA04001344A (es) Anticuerpos humanos antagonistas contra htnfsf13b.
EA201390278A1 (ru) Антитела к ох40 и способы их применения
WO2008079359A8 (en) Human antibodies that bind human il-12 and methods for producing
MX2022010665A (es) Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos.
BRPI0516260A (pt) antagonista de fator de necrose tumoral 1, ligante, monÈmero de anticorpo de domìnio (dab), ácido nucleico, vetor, célula hospedeira, métodos para produzir um polipeptìdeo, um monÈmero de dab, um ligante multiespecìfico, e um formato de anticorpo, e para tratar, suprimir ou prevenir uma doença, composição, uso de um antagonista, formato de anticorpo, polipeptìdeo, e, anticorpo ou fragmento de ligação de antìgeno do mesmo
WO2005016951A3 (en) Anti-ghrelin fab antibodies
MX2024006573A (es) Anticuerpos b7-h4 y anticuerpo anti-b7-h4/ proteinas de fusion il-15.
UA100531C2 (ru) Антитело, которое специфически связывается с тимическим стромальным лимфопоэтином (tslp)
UA84539C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с cd40, фармацевтическая композиция, которая его содержит, и применение антитела для производства лекарственного средства для лечения cd 40-отрицательной опухоли у человека
MY172707A (en) Il-12/p40 binding proteins
MX343996B (es) Anticuerpos humanos que ligan el tnfa humano.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 9A ANUIDADE.